Skip to main content

Advertisement

SpringerLink
Log in

Prognostıc Value of Increased her2 Expression in Cancers of Pancreas and Biliary Tree

  • Communication
  • Published:
Pathology & Oncology Research

Abstract

Increased HER2 expression has a prognostic, and predictive value in many solid cancer types, predominantly in breast cancer. However the effects of HER2 on survival from cancers of pancreas, gall bladder, cholangiocellular, and ampullary region are not known. In this study, the effects of increased HER2 expression on these types of cancer have been analyzed. Immunohistochemical HER2 staining was performed in 31 (44.9 %) female, and 38 (55.1 %) male patients with a mean age of 65 ± 10 years, and various parameters, mostly survival rates of patients with pancreas (n = 30; 43.5 %), gall bladder (n = 17; 24.6 %), cholangiocellular (n = 12; 17.4 %), and ampullary region (n = 10; 14.5 %) carcinomas were evaluated. Strong (3 +) membranous staining for HER2 was observed in 2 patients with gall bladder cancers (11.76 % of all gall bladder cancers). In 2.90 % of all cases strong membranous staining (2+ or 3+) was observed. Weak (1+) membranous staining was noted in one (3.33 %) pancreatic, and one cholangiocellular (8.33 %) cancer patient, and in none of the ampullary region patient membranous staining for HER2 was observed. Since only scarce number of patients demonstrated membranous staining for HER2, survival analysis was not performed on these patients. Based on cytoplasmic HER2 staining scores, the patients were divided into weakly (0–3 pts; n = 17 patients; 24.66 %), moderate (4–5 pts; n = 22; 31.88 %), and strongly (6–7 pts; n = 30; 43.46 %) stained groups. Patients whose specimens demonstrated borderline statistical significant (p = 0.052) low staining for HER2 had higher survival rates when compared with other cases. Increased HER2 expression has no prognostic, and predictive value in cancers of pancreas, biliary tract, and ampulla vateri. If HER2 will be evaluated in these types of cancer, membranous, as well as cytoplasmic staining properties should be taken into account.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Brenner H, Gondos A, Arndt V (2007) Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J Clin Oncol 25:3274–3280

    Article  PubMed  Google Scholar 

  2. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74

    Article  PubMed  Google Scholar 

  3. Klapper LN, Glathe S, Vaisman N et al (1999) The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 96:4995

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Giatromanolaki A, Koukourakis MI, Simopoulos C et al (2004) c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin Cancer Res 10:7972

    Article  CAS  PubMed  Google Scholar 

  5. Desmedt C, Sperinde J, Piette F et al (2009) Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol 18(1):22–29

    Article  CAS  PubMed  Google Scholar 

  6. Hudis CA (2007) Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357(1):39–51

    Article  CAS  PubMed  Google Scholar 

  7. Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28(7):1124–1130

    Article  CAS  PubMed  Google Scholar 

  8. Saxby AJ, Nielsen A, Scarlett CJ, Clarkson A, Morey A, Gill A, Smith RC (2005) Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol 29:1125–1134

    Article  PubMed  Google Scholar 

  9. Lei S, Appert HE, Nakata B, Domenico DR, Kim K, Howard JM (1995) Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol 17:15–21

    CAS  PubMed  Google Scholar 

  10. Koka V, Potti A, Koch M, Fraiman G, Mehdi S, Levitt R (2002) Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma. Anticancer Res 22:1593–1597

    CAS  PubMed  Google Scholar 

  11. Komoto M, Nakata B, Amano R, Yamada N, Yashiro M, Ohira M, Wakasa K, Hirakawa K. (2009 Jul) HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci 100

  12. Yoshimi N, DiGiovanni J (2001) Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 61:6971–6976

    PubMed  Google Scholar 

  13. Puhalla H, Wrba F, Kandioler D, Lehnert M, Huynh A, Gruenberger T, Tamandl D, Filipits M (2007) Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer. Anticancer Res 27(3B):1679–1684

    CAS  PubMed  Google Scholar 

  14. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T (2008 Jan 29) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98(2):418–25. Epub 2007 Dec 18

  15. Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graeff A, Opitz OG (2009) EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 15(36):4511–4517

    Article  PubMed Central  PubMed  Google Scholar 

  16. Baumhoer D, Zlobec I, Tornillo L, Dietmaier W, Wuensch PH, Hartmann A, Sessa F, Ruemmele P, Terracciano LM (2008 Dec) Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater. Virchows Arch 453(6):579–88. Epub 2008 Oct 21

  17. Albarello L, Pecciarini L, Doglioni C (2011) HER2 testing in gastric cancer. Adv Anat Pathol 18(1):53–59

    Article  CAS  PubMed  Google Scholar 

  18. Wolff AC, Hammond ME, Schwartz JN (2007) American Society of Clinical Oncology/Collage of American Pathologist Guideline recommendations for human epidermal factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18–43

    CAS  PubMed  Google Scholar 

  19. Tetu B, Brisson J (1994) Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 73:2359–2365

    Article  CAS  PubMed  Google Scholar 

  20. Coombs LM, Pigott DA, Sweeney E et al (1991) Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 63:601–608

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Kay EW, Mulcahy H, Walsh CB et al (1994) Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes’ B colorectal carcinoma. Histopathology 25:455–461

    Article  CAS  PubMed  Google Scholar 

  22. Roychowdhury DF, Tseng A, Fu KK et al (1996) New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and c-erbB-2 expression. Cancer 77:1419–1426

    Article  CAS  PubMed  Google Scholar 

  23. Hall PA, Hughes CM, Staddon SL et al (1990) The c-erb B-2 proto-oncogene in human pancreatic cancer. J Pathol 161:195–200

    Article  CAS  PubMed  Google Scholar 

  24. Sugg SL, Ezzat S, Zheng L et al (1998) Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia. Clin Endocrinol (Oxf) 49:629–637

    Article  CAS  Google Scholar 

  25. Hornick JL, Lauwers GY, Odze RD (2005) Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol 29(3):381–389

    Article  PubMed  Google Scholar 

  26. Moriya T, Kimura W, Semba S, Sakurai F, Hirai I, Ma J, Fuse A, Maeda K, Yamakawa M (2005) Biological similarities and differences between pancreatic intraepithelial neoplasias and intraductal papillary mucinous neoplasms. Int J Gastrointest Cancer 35(2):111–119

    Article  PubMed  Google Scholar 

  27. Bergmann F, Moldenhauer G, Herpel E, Gaida MM, Strobel O, Werner J, Esposito I, Müerköster SS, Schirmacher P, Kern MA (2010) Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets? Histopathology 56(4):440–448

    Article  CAS  PubMed  Google Scholar 

  28. Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL, Singh PK, Hollingsworth MA, Mehta PP, Batra SK (2008 Apr 1) MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res 68(7):2065–70. Erratum in: Cancer Res 2008 May 1;68(9):3550

  29. Tsiambas E, Karameris A, Dervenis C, Lazaris AC, Giannakou N, Gerontopoulos K, Patsouris E (2006) HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP 7(3):283–294

    PubMed  Google Scholar 

  30. Sharif S, Ramanathan RK, Potter D, Cieply K, Krasinskas AM (2008 Nov) HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. Dig Dis Sci 53(11):3026–32. Epub 2008 May 8

  31. Kaufman M, Mehrotra B, Limaye S, White S, Fuchs A, Lebowicz Y, Nissel-Horowitz S, Thomas A (2008) EGFR expression in gallbladder carcinoma in North America. Int J Med Sci 5(5):285–291

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Su WC, Shiesh SC, Liu HS, Chen CY, Chow NH, Lin XZ (2001) Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig Dis Sci 46(7):1387–1392

    Article  CAS  PubMed  Google Scholar 

  33. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE (2002) ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 36:439–450

    Article  CAS  PubMed  Google Scholar 

  34. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A (2005) Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206(3):356–365

    Article  CAS  PubMed  Google Scholar 

  35. Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F (2010) Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 10:631

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Haerslev T, Jacobsen GK (1993) Microwave processing of formalinfixed and paraffin-embedded sections improves the immunoreactivity of c-erbB-2 oncoprotein in breast carcinoma. Appl Immunohistochem 1:223–226

    Google Scholar 

  37. Keshgegian AA, Cnaan A et al (1997) erbB-2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody. Am J Clin Pathol 108:456–463

    CAS  PubMed  Google Scholar 

  38. Shafizadeh N, Grenert JP, Sahai V, Kakar S (2010) Apr Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. Hum Pathol 41(4):485–92. Epub 2009 Dec 29

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Mersin State Hospital, Mersin, Turkey

    Alper Ata

  2. Department of Pathology, Mersin University School of Medicine, Mersin, Turkey

    Ayşe Polat & Ebru Serinsöz

  3. Department of Biostatistics, Mersin University School of Medicine, Mersin, Turkey

    Mehmet Ali Sungur

  4. Department of Medical Oncology, Mersin University School of Medicine, Mersin, Turkey

    Ali Arican

Authors
  1. Alper Ata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ayşe Polat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ebru Serinsöz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehmet Ali Sungur
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ali Arican
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alper Ata.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ata, A., Polat, A., Serinsöz, E. et al. Prognostıc Value of Increased her2 Expression in Cancers of Pancreas and Biliary Tree. Pathol. Oncol. Res. 21, 831–838 (2015). https://doi.org/10.1007/s12253-014-9847-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-014-9847-x

Keywords

Search

Navigation